Dolutegravir + rilpivirine switch study (DORISS): Pilot and noninferiority trial comparing dolutegravir + rilpivirine vs. continued HAART (highly active antiretroviral therapy) in patients with plasma HIV RNA ≤ 50 copies/mL for at least 2 years

Trial Profile

Dolutegravir + rilpivirine switch study (DORISS): Pilot and noninferiority trial comparing dolutegravir + rilpivirine vs. continued HAART (highly active antiretroviral therapy) in patients with plasma HIV RNA ≤ 50 copies/mL for at least 2 years

Withdrawn prior to enrolment
Phase of Trial: Phase II/III

Latest Information Update: 01 Sep 2015

At a glance

  • Drugs Dolutegravir (Primary) ; Rilpivirine (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms DORISS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Aug 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as per ClinicalTrials.gov record.
    • 22 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top